Alvotech Past Earnings Performance
Past criteria checks 0/6
Alvotech's earnings have been declining at an average annual rate of -33.4%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 37.7% per year.
Key information
-33.4%
Earnings growth rate
86.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 37.7% |
| Return on equity | n/a |
| Net Margin | -112.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Alvotech's Position In The Coming Biosimilar Gold Rush
Nov 21Alvotech: Steady Progress Offers A Good Chance Of Upside
Aug 26Bullish: Analysts Just Made A Huge Upgrade To Their Alvotech (NASDAQ:ALVO) Forecasts
May 28
Alvotech: Consider Buying As Positive Q1 Earnings Release Likely
Apr 25Alvotech (NASDAQ:ALVO) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely
Apr 03Alvotech (NASDAQ:ALVO) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
Mar 24Analysts Just Shaved Their Alvotech (NASDAQ:ALVO) Forecasts Dramatically
Sep 03Positive Sentiment Still Eludes Alvotech (NASDAQ:ALVO) Following 27% Share Price Slump
May 05Shareholders Shouldn’t Be Too Comfortable With Alvotech's (NASDAQ:ALVO) Strong Earnings
Nov 23Fuji Pharma files for approval of biosimilar candidate in Japan
Oct 17Alvotech and STADA launch Humira biosimilar in Switzerland
Sep 22Revenue & Expenses Breakdown
How Alvotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 394 | -441 | 62 | 189 |
| 30 Jun 24 | 309 | -618 | 62 | 209 |
| 31 Mar 24 | 114 | -494 | 67 | 191 |
| 31 Dec 23 | 93 | -552 | 74 | 192 |
| 30 Sep 23 | 64 | -596 | 120 | 179 |
| 30 Jun 23 | 65 | -416 | 82 | 175 |
| 31 Mar 23 | 100 | -713 | 101 | 182 |
| 31 Dec 22 | 85 | -514 | 76 | 181 |
| 30 Sep 22 | 96 | 61 | 51 | 171 |
| 30 Jun 22 | 78 | -12 | 34 | 187 |
| 31 Mar 22 | 39 | -42 | 66 | 190 |
| 31 Dec 21 | 40 | -102 | 68 | 191 |
| 31 Dec 20 | 69 | -170 | 59 | 146 |
| 31 Dec 19 | 83 | -210 | 49 | 96 |
Quality Earnings: ALVO is currently unprofitable.
Growing Profit Margin: ALVO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALVO is unprofitable, and losses have increased over the past 5 years at a rate of 33.4% per year.
Accelerating Growth: Unable to compare ALVO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALVO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: ALVO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.